您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > ARL67156 trisodium hydrate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
ARL67156 trisodium hydrate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
ARL67156 trisodium hydrate图片
包装与价格:
包装价格(元)
1mg电议
5mg电议

产品名称
FPL 67156 trisodium hydrate
产品介绍
ARL67156 (FPL 67156) trisodium hydrate 是一种ecto-ATPase抑制剂。ARL67156 trisodium hydrate 是竞争性 NTPDase1 (CD39),NTPDase3 和 NPP1 抑制剂,Ki分别为 11,18 和 12 μM。ARL67156 trisodium hydrate 可用于钙化性主动脉瓣疾病、哮喘等疾病的研究。
生物活性

ARL67156 (FPL 67156) trisodium hydrate is a selectiveecto-ATPaseinhibitor. ARL67156 trisodium hydrate is a competitive inhibitor of NTPDase1 (CD39), NTPDase3 and NPP1, withKis of 11, 18 and 12 μM, respectively. ARL67156 trisodium hydrate can be used in the research of disease like calcific aortic valve disease, asthma[1][2].

IC50& Target

Ki: 11 μM (NTPDase1), 18 μM (NTPDase3), 12 μM (NPP1)[1]

体外研究
(In Vitro)

ARL67156 trisodium hydrate (1-100 μM) potentiates neurogenic contractions in a concentration-dependent manner[4].
ARL67156 trisodium hydrate (10 μg/mL, 24 h) increases the surface expression of CXCR3 on ATP-treated HMC-1 cells[5].
ARL67156 trisodium hydrate (30 μM, 5s) potentiates the norepinephrine release promoted by ATP in guinea pig heart synaptosomes[6].
ARL67156 trisodium hydrate (100 μM, 4h) significantly decreases HIV-1replication in macrophages[7].

体内研究
(In Vivo)

ARL67156 trisodium hydrate (1.1 μg/kg/day, administered with osmotic pumps implanted subcutaneously, for 28 days) prevents the development of calcific aortic valve disease in Warfarin (HY-B0687)-treated rats[2].
ARL67156 trisodium hydrate (intraperitoneal injection, 2 mg/kg) prevents the increase of serum adenosine concentration induced by Fructose 1,6-bisphosphate (FBP)[3].

Animal Model:Warfarin-induced mineralization rat model[2]
Dosage:1.1 μg/kg/day
Administration:Administered with osmotic pumps implanted subcutaneously, for 28 days
Result:Prevented the development of aortic stenosis by lowering the level of apoptosis and mineralization of the aortic valve/aorta.
Normalized the level of pAkt (an important kinase involved in the survival pathway).
Animal Model:C57BL/6 mice[3]
Dosage:2 mg/kg
Administration:Intraperitoneal injection, 1 h before administration of FBP (100 mg/kg)
Result:Completely abolished the anti-inflammatory effects of FBP (observed by the neutrophil infiltration, hyperalgesia and oedema of the joint).
分子量

834.61

性状

Solid

Formula

C15H23Br2N5Na3O13P3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

-20°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)